Health & bio
Late-April FDA Approvals Include HIV and Genetic Therapies
April 21: Idvynso (doravirine/islatravir) HIV-1 approval. April 23: Otarmeni accelerated approval for hereditary OTOF deafness gene therapy. April 29: Langlara (insulin glargine biosimilar) approval.
Primary sources · 1